FDA warns Lilly, Bayer on improper promos
The FDA has issued another wave of letters demanding changes in drug promotions. Warning letters went out to Bayer, Amylin Pharmaceuticals, Eli Lilly and Cephalon, ordering the companies to stop using DTC ads and other promos that either exaggerate a drug’s benefits or downplay its risks–or both. Here are the FDA’s beefs: A Lilly print ad for the antidepressant Cymbalta “entirely omits risk information,” directing readers to another page for that information, the FDA says. Another Cymbalta ad also downplayed the drug’s risk of side effects, the agency
